Microbiotica

Microbiotica’s timeline

2024

2025-04-29T14:16:06+01:0029 April 2025|

Microbiotica Announces First Patient Dosed in its Phase 1b Trial

2024

2025-04-29T14:16:51+01:0029 April 2025|

Microbiotica Announces First Patient Dosed in its International Phase 1b

2024

2025-04-29T14:17:06+01:0029 April 2025|

Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory

2022

2025-04-29T14:17:26+01:0029 April 2025|

Microbiotica announces transition of leadership, with Mark Romanos stepping down

2022

2025-04-29T14:17:34+01:0029 April 2025|

Microbiotica wins the Business Weekly Life Science Innovation award and

2022

2025-04-29T14:17:41+01:0029 April 2025|

Microbiotica raises £50 million ($67 million) to advance the pipeline

2020

2025-04-29T14:17:54+01:0029 April 2025|

Microbiotica assets MB097 and MB310 achieve preclinical proof of concept

2020

2025-04-29T14:18:10+01:0029 April 2025|

Microbiotica signs strategic collaboration in Immuno-oncology with Cancer Research UK

2020

2025-04-29T14:18:19+01:0029 April 2025|

Microbiotica’s Co-founder Professor Gordon Dougan receives the 2020 Albert B.